CLDF Title
Home | Contact Us | Bookmark
HBV HE HCC HCV
About CLDF Centers of Educational Expertise  
CME Dinner Meetings Telewebs Webcasts Slide Library Abstract Library Conference Highlights
 
Back  
 
Reuters Health Information (2005-06-22): Tumor cell antigens serve as novel liver cancer marker

Science

Tumor cell antigens serve as novel liver cancer marker

Last Updated: 2005-06-22 11:07:41 -0400 (Reuters Health)

NEW YORK (Reuters Health) - Serum levels of squamous cell carcinoma antigen (SCCA) immunoglobulin M (IgM) immune complexes (ICs) act as a biomarker for hepatocellular carcinoma and may make earlier detection possible, Italian researchers report in the June 15th issue of Cancer.

"Our findings on the discovery of a more sensitive and specific biomarker (SCCA-IC) for liver cancer are relevant not only to significantly improve current diagnostic accuracy in disease detection but more importantly in surveillance programs to more efficiently monitor at-risk patients," senior investigator Dr. Giorgio Fassina told Reuters Health.

Dr. Fassina of Xeptagen S.p.A., Pozzuoli and colleagues note that early detection of hepatocellular carcinoma is difficult because of the low specificity and sensitivity of current biomarkers. They recently found that SCCA variants were "overexpressed remarkably" in resected hepatocellular carcinomas.

The researchers compared the utility of serum levels of SCCA and alpha-fetoprotein. One hundred sixty serum samples from patients with various liver disorders and 73 serum samples from healthy controls were evaluated.

They found that 70% of liver cancer patients (35 of 50) showed serum reactive for SCCA-IgM IC, but the complex was undetectable in healthy controls.

Alpha-fetoprotein levels were significantly elevated in only 42% of the patients. However using a cut-off value for alpha-fetoprotein of 20 ng/mL, 96% of the patients were positive for at least one marker.

In cirrhotic patients, circulating SCCA-IgM IC was seen in 26% (13 of 50) but at significantly lower levels than in the cancer patients. Even lower levels were seen in the 9 of 50 (18%) of chronic hepatitis patients who were reactive.

The researchers note that hepatocellular carcinoma develops in more than 90% of patients who are affected by cirrhosis or chronic hepatitis and "mass screening may be justified."

Cancer 2005;103:2558-2565.

 
 
 
 
                 
 
HBV
Webcasts
Slide Library
Abstract Library
 
HE
CME Dinner Meeting
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
CLDF Follow Us
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors
CLDF Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Regional Map
     
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2014 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.